canagliflozin   Click here for help

GtoPdb Ligand ID: 4582

Synonyms: Invokana® | JNJ-28431754 | TA-7284
Approved drug
canagliflozin is an approved drug (FDA & EMA (2013))
Compound class: Synthetic organic
Comment: Marketed formulations may contain canagliflozin in a hemihydrate form (PubChem CID 24997615).
Click here for help
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: canagliflozin

2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 4
Rotatable bonds 5
Topological polar surface area 118.39
Molecular weight 444.14
XLogP 3.2
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES OCC1OC(c2ccc(c(c2)Cc2ccc(s2)c2ccc(cc2)F)C)C(C(C1O)O)O
Isomeric SMILES OC[C@H]1O[C@@H](c2ccc(c(c2)Cc2ccc(s2)c2ccc(cc2)F)C)[C@@H]([C@H]([C@@H]1O)O)O
InChI InChI=1S/C24H25FO5S/c1-13-2-3-15(24-23(29)22(28)21(27)19(12-26)30-24)10-16(13)11-18-8-9-20(31-18)14-4-6-17(25)7-5-14/h2-10,19,21-24,26-29H,11-12H2,1H3/t19-,21-,22+,23-,24+/m1/s1
No information available.
Summary of Clinical Use Click here for help
Canagliflozin is an anti-diabetic drug, used to improve glycemic control in adults with type 2 diabetes mellitus. Canagliflozin is combined with metformin in Invokamet®, the first fixed-dose combination of an SGLT2 inhibitor with metformin to be approved (by the US FDA, 2014).
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Canagliflozin inhibits the sodium/glucose cotransporter 2 (SLC5A2). Inhibition of this transporter in the proximal renal tubules reduces reabsorption of glucose, thereby increasing urinary glucose excretion.
External links Click here for help